Sokoya Itunuoluwa Dorcas

Sokoya Itunuoluwa Dorcas

Auto-generated profile, based on publicly available information

Sokoya Itunuoluwa Dorcas

Onabanjo University Teaching Hospital, Sagamu, Ogun state, Nigeria

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2025 in Asian Journal of Microbiology and Biotechnology
Verified
Journal Article
Closed access
OLOlabisi Promise Lawal
Olabisi Promise Lawal
OAOlufemi Adesola Adedayo
Olufemi Adesola Adedayo
SDSokoya Itunuoluwa Dorcas
Sokoya Itunuoluwa Dorcas
OAOlukunle O. Akanbi
Olukunle O. Akanbi
BOBostock Chinecherem Okafor
Bostock Chinecherem Okafor
ABAbdullateef M. Busari
Abdullateef M. Busari
Tuberculosis (TB) still presents a major threat to public health, and accurate diagnosis of tuberculosis, monitoring TB treatment, as well as TB drug resistance are still challenging goals. Research in biomarkers—both host, pathogen pathogen-derived—has led to novel frontiers in the diagnosis and management of TB. These advancements contribute to faster diagnosis, customized treatment plans, and better monitoring of response to therapy. Direct pathogen-based markers, such as M. tuberculosis DNA, lipoarabinomannan (LAM), and mycobacterial proteins, that directly demonstrate infection, have the most potential, particularly in resource-poor settings. Cytokines such as interferon-gamma (IFN-γ) and inflammatory markers, such as C-reactive protein (CRP), are endogenous biomarkers that mirror responses of the immune system and may play a role in the management of treatment, especially in immunocompromised populations, such as patients with HIV. These progresses notwithstanding, the application of a biomarker-centered approach on a large scale remains a major obstacle, due to technical, economic, and regulatory constraints. Furthermore, various performances among the biomarkers in different populations limit clinical utility. Future studies in this area should aim to create point-of-care diagnostics, multi-biomarker panels, and to integrate the device with digital health technology platforms for real-time monitoring. These methods have the potential to substantially improve TB control, particularly in low- and middle-income countries. If current challenges can be overcome and research horizons broadened, biomarker-driven diagnosis and monitoring strategies may have key contributions in global TB control.

20 June 2025 in Journal of Life Science and Public Health
Verified
Journal Article
Open access
PDF file
OLOlabisi Promise Lawal
Olabisi Promise Lawal
EOEnibokun Theresa Orobator
Enibokun Theresa Orobator
SDSokoya Itunuoluwa Dorcas
Sokoya Itunuoluwa Dorcas
VEVictor Chiedozie Ezeamii
Victor Chiedozie Ezeamii
EFEvelyn Foster-Pagaebi
Evelyn Foster-Pagaebi
MAMuhammad Attahiru
Muhammad Attahiru
Orphan drug development for rare diseases presents unique challenges that require targeted scientific, economic, and policy-based responses. With over 300 million individuals globally affected by rare diseases, the need for effective therapies is urgent. However, development is hindered by limited biological understanding, small patient populations, and difficulties in clinical trial recruitment. High research and development costs and inconsistent market incentives further discourage investment, especially in low- and middle-income countries (LMICs). Ethical concerns around access and affordability deepen disparities. To address these issues, legislative measures such as the U.S. Orphan Drug Act and similar policies in the EU and Japan offer benefits like market exclusivity and expedited regulatory review. Advances in genomic sequencing, artificial intelligence, and real-world data are enhancing diagnostics and drug discovery. Collaborative research models, adaptive trial designs, and decentralized clinical trials improve feasibility and inclusivity. Equity-driven frameworks such as tiered pricing and support for local manufacturing are critical to expanding access in LMICs.This article examines the interconnected challenges of orphan drug development and outlines evidence-based strategies to improve therapeutic innovation and global access. A coordinated, multisectoral effort is essential to ensure that the benefits of precision medicine and translational research extend beyond high-income countries and contribute to global health equity.